2025
Decline in Community-Acquired Alveolar Pneumonia Positive for Respiratory Syncytial Virus in Hospitalized Children Following Implementation of Pneumococcal Conjugate Vaccine (PCV) in Israel
Dagan R, van der Beek B, Grupel T, Greenberg D, Keren-Naus A, Ben-Shimol S, Weinberger D. Decline in Community-Acquired Alveolar Pneumonia Positive for Respiratory Syncytial Virus in Hospitalized Children Following Implementation of Pneumococcal Conjugate Vaccine (PCV) in Israel. Clinical Infectious Diseases 2025, ciaf102. PMID: 40052957, DOI: 10.1093/cid/ciaf102.Peer-Reviewed Original ResearchPneumococcal conjugate vaccineImpact of pneumococcal conjugate vaccinesConjugate vaccineCommunity-acquired alveolar pneumoniaPneumococcal conjugate vaccine implementationImplementation of pneumococcal conjugate vaccinesRespiratory syncytial virusAnnual hospitalization rateCommunity-acquiredAlveolar pneumoniaSyncytial virusPCV13 implementationAnnual incidenceYoung childrenHospitalization ratesIncidenceRSVMonthsVaccineChildrenEpisodesRegression modelsSynergistic rolePCV13Binomial regression modelsEstimating the Serotype-Specific Association Between the Concentration of Vaccine-Induced Serum Antibodies and Protection Against Pneumococcal Colonization
Wong A, Warren J, Fitch L, Perniciaro S, Dagan R, Weinberger D. Estimating the Serotype-Specific Association Between the Concentration of Vaccine-Induced Serum Antibodies and Protection Against Pneumococcal Colonization. The Journal Of Infectious Diseases 2025, 232: e27-e34. PMID: 40036886, PMCID: PMC12308679, DOI: 10.1093/infdis/jiaf106.Peer-Reviewed Original ResearchHigher-valent PCVsPneumococcal conjugate vaccinePneumococcal colonizationVaccine-induced serum antibodiesRisk of colonizationSerum immunoglobulin GRandomized Controlled TrialsConjugate vaccinePCV13Clinical trialsSerum IgGImmune responseVaccinated childrenSevere diseaseVaccine effectivenessSerum antibodiesPCV20Serotype-specificImmunoglobulin GSerotypesColonIndirect protectionIgGVaccineTrials
2022
Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data
Ryman J, Weaver J, Hu T, Weinberger D, Yee K, Sachs J. Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data. Npj Vaccines 2022, 7: 140. PMID: 36344529, PMCID: PMC9640717, DOI: 10.1038/s41541-022-00538-1.Peer-Reviewed Original ResearchPneumococcal conjugate vaccineSerotype-specific IgG concentrationsInvasive pneumococcal diseaseVaccine effectivenessIgG concentrationsPneumococcal diseaseImmune responseAntibody concentrationsProtective antibody concentrationsNext-generation vaccinesPCV13 recipientsConjugate vaccineImmunogenicity dataPCV7PCV13SerotypesVaccineDiseasePlaceboImmunogenicityRecipients
2021
Real-time monitoring of the rollout of pneumococcal conjugate vaccines in rural India using a digital tracking platform
Nagar R, Ambiya M, Dalal S, Bhadauriya P, Abdullah H, Shahnawaz M, Weinberger D. Real-time monitoring of the rollout of pneumococcal conjugate vaccines in rural India using a digital tracking platform. Gates Open Research 2021, 5: 16. DOI: 10.12688/gatesopenres.13206.1.Peer-Reviewed Original ResearchPneumococcal conjugate vaccineBooster doseConjugate vaccineImmunization programsRoutine immunization programPercent of childrenMonths of ageFirst doseThird doseVaccination statusPrimary dosesSecond dosePneumococcal transmissionVaccine programDigital health platformPCV13Vaccine deliveryOnly dosesDoseMaximal benefitVaccineTime pointsRural IndiaDosesHealth platform
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply